Corbus Pharmaceuticals Hldgs Inc (CRBP)

Jan 15, 2026, 3:15 PM EST - 19 days ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 5, 2026, 7:30 AM EST - 4 weeks ago

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:42 PM EST - 7 weeks ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript

Dec 11, 2025, 7:00 AM EST - 7 weeks ago

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Dec 10, 2025, 4:01 PM EST - 7 weeks ago

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Nov 6, 2025, 8:00 AM EST - 3 months ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 5, 2025, 11:42 AM EST - 3 months ago

Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Oct 31, 2025, 2:40 AM EDT - 3 months ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Oct 30, 2025, 4:31 PM EDT - 3 months ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Oct 20, 2025, 5:05 PM EDT - 3 months ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Oct 18, 2025, 3:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Sep 16, 2025, 8:00 AM EDT - 5 months ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Jun 25, 2025, 8:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 24, 2025, 4:05 PM EDT - 8 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 17, 2025, 3:42 PM EDT - 8 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

May 22, 2025, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Mar 28, 2025, 8:00 AM EDT - 11 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Feb 14, 2025, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 11, 2025, 7:30 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Jan 28, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 6, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 3, 2024, 7:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 11, 2024, 4:12 AM EST - 1 year ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 2 years ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:13 AM EST - 2 years ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 29, 2024, 2:17 PM EST - 2 years ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 7:18 AM EST - 2 years ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?